Quantitative proteomics reveals proteins involved in the progression from non-cancerous lesions to gastric cancer
Por:
Fernández-Coto D.L., Gil J., Hernández A., Herrera-Goepfert R., Castro-Romero I., Hernández-Márquez E., Arenas-Linares A.S., Calderon-Sosa V.T., Sanchez-Aleman M.Á., Mendez-Tenorio A., Encarnación-Guevara S., Ayala G.
Publicada:
30 ago 2018
Ahead of Print:
1 ene 2018
Resumen:
Gastric cancer is one of the most aggressive malignancies affecting
humankind. With almost a million cases globally, it sits in fifth
position in terms of incidence, and third in terms of mortality. The
progression of this disease is slow, with prolonged and sequential
precancerous stages including chronic gastritis, intestinal metaplasia,
dysplasia, and finally gastric cancer. Here we used the iTRAQ approach
combined with high-resolution mass spectrometry analysis to describe the
spectrum of the gastric cancer cascade. Biopsies from three stages:
chronic gastritis, intestinal metaplasia, and gastric adenocarcinoma,
were selected for analysis by quantitative proteomics. We identified and
reported quantitative data for 3914 different proteins quantified with
high confidence, uncovering pathways and processes dysregulated between
the different stages. Intestinal metaplasia is characterized by the
down-regulation of ribosomal proteins, with overexpression of cell
survival proteins such as GSTP1 and EPCAM. The transformation to gastric
cancer involves overexpression of the DNA replication and the
spliceosome pathways. The impairment of mitochondrial pathways was
correlated with down-regulation of SIRT3 and SIRT5, and overexpression
of enzymes supporting the glycolytic phenotype, such as HK3 and PCK2.
Several proteins found dysregulated during the progression of gastric
cancer have potential to be used as specific biomarkers and/or
therapeutic targets.
Filiaciones:
Fernández-Coto D.L.:
Instituto Nacional de Salud Pública, Universidad No. 655, Col. Santa María Ahuacatitlán, Cuernavaca, Morelos, Mexico
Laboratorio de Biotecnología y Bioinformática Genómica ENCB, Instituto Politécnico Nacional CDMX, Mexico
Gil J.:
Programa de Genómica Funcional de Procariotes, Centro de Ciencias Genómicas-UNAM, Universidad s/n, Col. Chamilpa, Cuernavaca, Morelos, Mexico
Hernández A.:
Instituto Nacional de Cancerología, Mexico
Herrera-Goepfert R.:
Instituto Nacional de Cancerología, Mexico
Castro-Romero I.:
Instituto Nacional de Salud Pública, Universidad No. 655, Col. Santa María Ahuacatitlán, Cuernavaca, Morelos, Mexico
Hernández-Márquez E.:
Instituto Nacional de Salud Pública, Universidad No. 655, Col. Santa María Ahuacatitlán, Cuernavaca, Morelos, Mexico
Arenas-Linares A.S.:
Instituto Nacional de Salud Pública, Universidad No. 655, Col. Santa María Ahuacatitlán, Cuernavaca, Morelos, Mexico
Calderon-Sosa V.T.:
Instituto Nacional de Cancerología, Mexico
Sanchez-Aleman M.Á.:
Instituto Nacional de Salud Pública, Universidad No. 655, Col. Santa María Ahuacatitlán, Cuernavaca, Morelos, Mexico
Mendez-Tenorio A.:
Laboratorio de Biotecnología y Bioinformática Genómica ENCB, Instituto Politécnico Nacional CDMX, Mexico
Encarnación-Guevara S.:
Programa de Genómica Funcional de Procariotes, Centro de Ciencias Genómicas-UNAM, Universidad s/n, Col. Chamilpa, Cuernavaca, Morelos, Mexico
Ayala G.:
Instituto Nacional de Salud Pública, Universidad No. 655, Col. Santa María Ahuacatitlán, Cuernavaca, Morelos, Mexico
|